Next year’s Medicare Part B premiums are expected to be announced soon and there is speculation that coverage of another pricey new Alzheimer’s medication could cause monthly costs to go up, echoing what occurred in 2022. Leqembi received full approval from the Food and Drug Administration (FDA) in July, becoming …
Read More »